846 related articles for article (PubMed ID: 32248071)
21. Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: A narrative review apropos of a case.
Apalla Z; Kemanetzi C; Papageorgiou C; Bobos M; Manoli M; Fotiadou C; Hatzibougias D; Boukovinas I; Stergiou E; Levva S; Lallas A; Lazaridou E
Dermatol Ther; 2021 Jan; 34(1):e14618. PubMed ID: 33263945
[TBL] [Abstract][Full Text] [Related]
22. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy.
Balanescu DV; Donisan T; Palaskas N; Lopez-Mattei J; Kim PY; Buja LM; McNamara DM; Kobashigawa JA; Durand JB; Iliescu CA
Cardiovasc Pathol; 2020; 47():107211. PubMed ID: 32268262
[TBL] [Abstract][Full Text] [Related]
23. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
Gao CA; Weber UM; Peixoto AJ; Weiss SA
J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
[TBL] [Abstract][Full Text] [Related]
24. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
[TBL] [Abstract][Full Text] [Related]
25. Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.
Danlos FX; Pagès C; Baroudjian B; Vercellino L; Battistella M; Mimoun M; Jebali M; Bagot M; Tazi A; Lebbé C
Chest; 2016 May; 149(5):e133-6. PubMed ID: 27157227
[TBL] [Abstract][Full Text] [Related]
26. Erythema Nodosum as the Initial Presentation of Nivolumab-Induced Sarcoidosis-Like Reaction.
Laroche A; Alarcon Chinchilla E; Bourgeault E; Doré MA
J Cutan Med Surg; 2018; 22(6):627-629. PubMed ID: 29772919
[TBL] [Abstract][Full Text] [Related]
27. Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy.
Nomura H; Takahashi H; Suzuki S; Kurihara Y; Chubachi S; Kawada I; Yasuda H; Betsuyaku T; Amagai M; Funakoshi T
J Dermatol; 2017 Jul; 44(7):818-821. PubMed ID: 28295542
[TBL] [Abstract][Full Text] [Related]
28. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
29. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.
Tetzlaff MT; Nelson KC; Diab A; Staerkel GA; Nagarajan P; Torres-Cabala CA; Chasen BA; Wargo JA; Prieto VG; Amaria RN; Curry JL
J Immunother Cancer; 2018 Feb; 6(1):14. PubMed ID: 29433571
[TBL] [Abstract][Full Text] [Related]
30. Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.
Zezza M; Kosinski C; Mekoguem C; Marino L; Chtioui H; Pitteloud N; Lamine F
BMC Endocr Disord; 2019 Dec; 19(1):144. PubMed ID: 31870373
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
[TBL] [Abstract][Full Text] [Related]
32. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
33. Three cases of nivolumab therapy-failed advanced melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy.
Amagai R; Fujimura T; Kambayashi Y; Sato Y; Tanita K; Hashimoto A; Aiba S
J Dermatol; 2019 May; 46(5):449-452. PubMed ID: 30908705
[TBL] [Abstract][Full Text] [Related]
34. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
Asher N; Marom EM; Ben-Betzalel G; Baruch EN; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
Oncologist; 2019 May; 24(5):640-647. PubMed ID: 30777894
[TBL] [Abstract][Full Text] [Related]
35. Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission.
Yatim N; Mateus C; Charles P
Rev Med Interne; 2018 Feb; 39(2):130-133. PubMed ID: 29277453
[TBL] [Abstract][Full Text] [Related]
36. Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma.
Gupta M; Stukalin I; Meyers D; Goutam S; Heng DYC; Cheng T; Monzon J; Navani V
JAMA Netw Open; 2023 Jun; 6(6):e2319607. PubMed ID: 37351883
[TBL] [Abstract][Full Text] [Related]
37. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
Bhave P; Pallan L; Long GV; Menzies AM; Atkinson V; Cohen JV; Sullivan RJ; Chiarion-Sileni V; Nyakas M; Kahler K; Hauschild A; Plummer R; Trojaniello C; Ascierto PA; Zimmer L; Schadendorf D; Allayous C; Lebbe C; Maurichi A; Santinami M; Roy S; Robert C; Lesimple T; Patel S; Versluis JM; Blank CU; Khattak A; Van der Westhuizen A; Carlino MS; Shackleton M; Haydon A
Br J Cancer; 2021 Feb; 124(3):574-580. PubMed ID: 33087895
[TBL] [Abstract][Full Text] [Related]
38. Serious disseminated intravascular coagulation associated with combination therapy of nivolumab and ipilimumab in advanced melanoma.
Kuriyama H; Fukushima S; Nakahara S; Kanemaru H; Miyashita A; Aoi J; Tomita Y; Kawasaki T; Nosaka K; Ihn H
J Dermatol; 2020 Jun; 47(6):e235-e237. PubMed ID: 32275077
[No Abstract] [Full Text] [Related]
39. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
40. Multiple sclerosis outcomes after cancer immunotherapy.
Garcia CR; Jayswal R; Adams V; Anthony LB; Villano JL
Clin Transl Oncol; 2019 Oct; 21(10):1336-1342. PubMed ID: 30788836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
